Pluri Inc. Share-based Payment Arrangement, Expense
Pluri Inc. (PLUR) reported Share-based Payment Arrangement, Expense of $395.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-05-14
- Pluri Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $395.00K, a 14.69% decline year-over-year.
- Pluri Inc. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $463.00K, a 976.74% increase year-over-year.
- Pluri Inc. share-based payment arrangement, expense for the quarter ending 2024-06-30 was $53.00K, a 5.36% decline year-over-year.
- Pluri Inc. share-based payment arrangement, expense for the quarter ending 2024-03-31 was $43.00K, a 23.21% decline year-over-year.
- Pluri Inc. share-based payment arrangement, expense for fiscal 2024 was $170.00K, a 17.07% decline from fiscal 2023.
- Pluri Inc. share-based payment arrangement, expense for fiscal 2023 was $205.00K.
| Period end | Share-based Payment Arrangement, Expense 1 month | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $395.00K 10-Q · filed 2026-05-14 | $1.78M 10-Q · filed 2026-05-14 | |||
| 2025-03-31 | $463.00K 10-Q · filed 2026-05-14 | $1.17M 10-Q · filed 2026-05-14 | |||
| 2024-06-30 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-18 | $96.00K derived: sum of 2 quarters · filed 2024-09-18 | $132.00K derived: sum of 3 quarters · filed 2024-09-18 | $170.00K 10-K · filed 2024-09-18 | |
| 2024-03-31 | $43.00K 10-Q · filed 2024-05-09 | $79.00K derived: sum of 2 quarters · filed 2024-05-09 | $117.00K 10-Q · filed 2024-05-09 | $173.00K derived: sum of 4 quarters · filed 2024-09-18 | |
| 2023-12-31 | $36.00K 10-Q · filed 2024-02-12 | $74.00K 10-Q · filed 2024-02-12 | $130.00K derived: sum of 3 quarters · filed 2024-09-18 | $186.00K derived: sum of 4 quarters · filed 2024-09-18 | |
| 2023-09-30 | $38.00K 10-Q · filed 2023-11-13 | $94.00K derived: sum of 2 quarters · filed 2024-09-18 | $150.00K derived: sum of 3 quarters · filed 2024-09-18 | $205.00K derived: sum of 4 quarters · filed 2024-09-18 | |
| 2023-06-30 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-18 | $112.00K derived: sum of 2 quarters · filed 2024-09-18 | $167.00K derived: sum of 3 quarters · filed 2024-09-18 | $205.00K 10-K · filed 2024-09-18 | |
| 2023-03-31 | $56.00K 10-Q · filed 2024-05-09 | $111.00K derived: sum of 2 quarters · filed 2024-05-09 | $149.00K 10-Q · filed 2024-05-09 | ||
| 2022-12-31 | $55.00K 10-Q · filed 2024-02-12 | $93.00K 10-Q · filed 2024-02-12 | |||
| 2022-09-30 | $38.00K 10-Q · filed 2023-11-13 | ||||
| 2022-03-31 | $56.00K 10-Q · filed 2023-05-09 | $125.00K derived: sum of 2 quarters · filed 2023-05-09 | $195.00K 10-Q · filed 2023-05-09 | ||
| 2022-02-26 | $1.65M 10-K · filed 2023-09-12 | ||||
| 2021-12-31 | $69.00K 10-Q · filed 2023-02-13 | $139.00K 10-Q · filed 2023-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |